To target MET in GBM patients, clinically approved MET inhibitors (such as the multi‐kinase inhibitor Crizotinib) are available, and new compounds, either small molecules or antibodies, are under development (Peters & Adjei, 2012; Vigna & Comoglio, 2015). This evidence concerns the gene MET and glioblastoma.